CymaBay Therapeutics, Inc. Made Headway
Mon, Aug 03, 2020 at 05:30 PM
CymaBay Therapeutics, Inc. (CBAY:NASDAQ) soared at $4.88, representing a gain of 37.5%. On Fri 31 Jul 20, CBAY:NASDAQ touched a New 2-Week Intraday Low of $3.47. The stock got featured on our News Catalysts scanner on Mon 03 Aug 20 at 04:44 PM in the 'EARNINGS' category. From Fri 17 Jul 20, the stock recorded 30.00% Up Days and 18.18% Green Days
The stock spiked on Thu 23 Jul 20 at $5.08 with a volume of 44M+, and its share price has been moving sideways in recent weeks.
About CymaBay Therapeutics, Inc. (CBAY:NASDAQ)
CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.
Top 10 Gainers:
- Marathon Patent Group, Inc. (MARA:NASDAQ), 88.67%
- Moxian, Inc. (MOXC:NASDAQ), 71.91%
- Grindrod Shipping Holdings Ltd. (GRIN:NASDAQ), 69.81%
- EuroDry Ltd. (EDRY:NASDAQ), 59.73%
- ADT Inc. (ADT:NYSE), 56.56%
- Cohen & Company Inc. (COHN:NYSEMKT), 50.65%
- Pitney Bowes Inc. (PBI:NYSE), 46.41%
- Ambow Education Holding Ltd. (AMBO:NYSEMKT), 40.91%
- CymaBay Therapeutics, Inc. (CBAY:NASDAQ), 37.46%
- Highway Holdings Limited (HIHO:NASDAQ), 36.88%